Amyloid-beta (1-40) and the risk of death from cardiovascular causes in patients with coronary heart disease.

[1]  L. Kuller,et al.  Arterial stiffness and β-amyloid progression in nondemented elderly adults. , 2014, JAMA neurology.

[2]  D. Dash,et al.  Amyloid β peptide stimulates platelet activation through RhoA‐dependent modulation of actomyosin organization , 2014, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[3]  D. Allsop,et al.  β-Amyloid Fibrils in Alzheimer Disease Are Not Inert When Bound to Copper Ions but Can Degrade Hydrogen Peroxide and Generate Reactive Oxygen Species* , 2014, The Journal of Biological Chemistry.

[4]  J. Fleg,et al.  Secondary prevention of atherosclerotic cardiovascular disease in older adults: a scientific statement from the American Heart Association. , 2013, Circulation.

[5]  J. Lekakis,et al.  Lipoprotein-associated phospholipase A(2) bound on high-density lipoprotein is associated with lower risk for cardiac death in stable coronary artery disease patients: a 3-year follow-up. , 2012, Journal of the American College of Cardiology.

[6]  Deborah Blacker,et al.  Plasma amyloid-β as a predictor of dementia and cognitive decline: a systematic review and meta-analysis. , 2012, Archives of neurology.

[7]  H. Tsao,et al.  Amyloid peptide regulates calcium homoeostasis and arrhythmogenesis in pulmonary vein cardiomyocytes , 2012, European journal of clinical investigation.

[8]  J. Wiltfang,et al.  Stability of amyloid‐β peptides in plasma and serum , 2012, Electrophoresis.

[9]  T. Beach,et al.  Chemical characterization of pro-inflammatory amyloid-beta peptides in human atherosclerotic lesions and platelets. , 2011, Biochimica et biophysica acta.

[10]  A. Kastrati,et al.  High-sensitivity troponin T level and angiographic severity of coronary artery disease. , 2011, The American journal of cardiology.

[11]  F. Grodstein,et al.  Plasma amyloid-beta as a predictor of dementia and cognitive decline: A systematic review and meta-analysis , 2011, Alzheimer's & Dementia.

[12]  P. Guns,et al.  Attenuated atherogenesis in apolipoprotein E-deficient mice lacking amyloid precursor protein. , 2011, Atherosclerosis.

[13]  S. Strickland,et al.  Alzheimer's disease peptide β-amyloid interacts with fibrinogen and induces its oligomerization , 2010, Proceedings of the National Academy of Sciences.

[14]  A. Maggi,et al.  Increased atherosclerosis and vascular inflammation in APP transgenic mice with apolipoprotein E deficiency. , 2010, Atherosclerosis.

[15]  C. Vlachopoulos,et al.  Prediction of Cardiovascular Events and All-Cause Mortality With Arterial Stiffness , 2011 .

[16]  M. Mogi,et al.  Cognitive Deficit in Amyloid-&bgr;–Injected Mice Was Improved by Pretreatment With a Low Dose of Telmisartan Partly Because of Peroxisome Proliferator-Activated Receptor-&ggr; Activation , 2009, Hypertension.

[17]  G. Kitas,et al.  Atherosclerosis in Rheumatoid Arthritis Versus Diabetes: A Comparative Study , 2009, Arteriosclerosis, thrombosis, and vascular biology.

[18]  R. Martins,et al.  Clearance mechanisms of Alzheimer's amyloid-β peptide: implications for therapeutic design and diagnostic tests , 2009, Molecular Psychiatry.

[19]  L. Lue,et al.  Expression of inflammatory genes induced by beta-amyloid peptides in human brain endothelial cells and in Alzheimer's brain is mediated by the JNK-AP1 signaling pathway , 2009, Neurobiology of Disease.

[20]  D. Teplow,et al.  Identification of antihypertensive drugs which inhibit amyloid-beta protein oligomerization. , 2009, Journal of Alzheimer's disease : JAD.

[21]  Wei Zhao,et al.  Valsartan lowers brain beta-amyloid protein levels and improves spatial learning in a mouse model of Alzheimer disease. , 2007, The Journal of clinical investigation.

[22]  Tony Wyss-Coray,et al.  Inflammation in Alzheimer disease: driving force, bystander or beneficial response? , 2006, Nature Medicine.

[23]  M. Fornerod,et al.  Characterization of the Drosophila melanogaster genome at the nuclear lamina , 2006, Nature Genetics.

[24]  S. Melov,et al.  Alzheimer disease β-amyloid activity mimics cholesterol oxidase , 2005 .

[25]  S. Melov,et al.  Alzheimer disease beta-amyloid activity mimics cholesterol oxidase. , 2005, The Journal of clinical investigation.

[26]  Eric J Topol,et al.  Convergence of atherosclerosis and Alzheimer's disease: inflammation, cholesterol, and misfolded proteins , 2004, The Lancet.

[27]  K. Moore,et al.  Fibrillar Amyloid Protein Present in Atheroma Activates CD36 Signal Transduction* , 2004, Journal of Biological Chemistry.

[28]  Ann Marie Schmidt,et al.  RAGE mediates amyloid-β peptide transport across the blood-brain barrier and accumulation in brain , 2003, Nature Medicine.

[29]  Y. Suh,et al.  Effects of the β-Amyloid and Carboxyl-terminal Fragment of Alzheimer's Amyloid Precursor Protein on the Production of the Tumor Necrosis Factor-α and Matrix Metalloproteinase-9 by Human Monocytic THP-1* , 2001, The Journal of Biological Chemistry.

[30]  C. Bergmann,et al.  Simvastatin strongly reduces levels of Alzheimer's disease β-amyloid peptides Aβ42 and Aβ40 in vitro and in vivo , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[31]  M. Hennerici,et al.  Simvastatin strongly reduces levels of Alzheimer's disease beta -amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[32]  J. Treanor,et al.  Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. , 1999, Science.

[33]  M. Mullan,et al.  β-Amyloid-mediated vasoactivity and vascular endothelial damage , 1996, Nature.

[34]  M. Mullan,et al.  beta-Amyloid-mediated vasoactivity and vascular endothelial damage. , 1996, Nature.